ABCELLERA BIOLOGICS INC's ticker is ABCL and the CUSIP is 00288U106. A total of 131 filers reported holding ABCELLERA BIOLOGICS INC in Q1 2022. The put-call ratio across all filers is 0.31 and the average weighting 1.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,429,063 | -67.2% | 1,180,231 | -54.0% | 0.00% | -66.7% |
| Q2 2023 | $16,556,786 | +18.3% | 2,562,970 | +38.1% | 0.00% | 0.0% |
| Q1 2023 | $13,994,089 | -31.8% | 1,855,980 | -8.3% | 0.00% | -25.0% |
| Q4 2022 | $20,510,170 | +85.9% | 2,024,696 | +81.5% | 0.00% | +100.0% |
| Q3 2022 | $11,034,000 | +25.5% | 1,115,648 | +35.1% | 0.00% | 0.0% |
| Q2 2022 | $8,792,000 | +97.1% | 825,500 | +80.4% | 0.00% | – |
| Q1 2022 | $4,461,000 | -59.2% | 457,542 | -40.2% | 0.00% | -100.0% |
| Q4 2021 | $10,941,000 | -24.3% | 765,090 | +6.1% | 0.00% | -33.3% |
| Q3 2021 | $14,456,000 | -16.1% | 721,319 | -7.9% | 0.00% | -25.0% |
| Q2 2021 | $17,237,000 | +148.7% | 783,509 | +283.9% | 0.00% | +300.0% |
| Q1 2021 | $6,931,000 | -60.2% | 204,075 | -52.8% | 0.00% | -80.0% |
| Q4 2020 | $17,398,000 | – | 432,357 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Founders Fund VII Management, LLC | 3,773,530 | $17,358,238 | 89.37% |
| Founders Fund Growth Management, LLC | 407,017 | $1,872,278 | 5.10% |
| Prosight Management, LP | 2,446,000 | $11,251,600 | 3.57% |
| Intellectus Partners, LLC | 876,633 | $4,032,511 | 1.28% |
| Belmont Capital, LLC | 510,000 | $2,346,000 | 1.27% |
| Casdin Capital, LLC | 2,360,129 | $10,856,593 | 1.20% |
| GUARDIAN CAPITAL ADVISORS LP | 1,786,414 | $7,842,357 | 0.88% |
| Baker Brothers Advisors | 20,763,323 | $95,511,286 | 0.55% |
| BRANDYWINE MANAGERS, LLC | 56,976 | $262,090 | 0.44% |
| Orbimed Advisors | 4,180,768 | $19,231,533 | 0.41% |